FUSAROLI, MICHELE
FUSAROLI, MICHELE
DIMEC - DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Characterizing post-mortem blood concentrations in methadone-related deaths
2026 Pelletti, Guido; Giunchi, Valentina; Fais, Paolo; Innocenti, Mattia; Giorgetti, Arianna; Poluzzi, Elisabetta; Fusaroli, Michele; Pelotti, Susi
Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study
2025 Bernardeau, Claire; Revol, Bruno; Salvo, Francesco; Fusaroli, Michele; Raschi, Emanuel; Cracowski, Jean-Luc; Roustit, Matthieu; Khouri, Charles
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency
2025 Giunchi, Valentina; Fusaroli, Michele; Cangini, Agnese; Fortinguerra, Filomena; Zito, Simona; Pierantozzi, Andrea; Lunghi, Carlotta; Poluzzi, Elisabetta; Trotta, Francesco
Ivabradine, atrial fibrillation and stroke: a combined meta-analysis and FAERS disproportionality analysis
2025 Spadotto, A.; Fusaroli, M.; Carelli, M.; Nardi, E.; Amadori, M.; Massaro, G.; De Angelis, V.; Gatti, M.; Ciubine, V.; Raschi, E.; Poluzzi, E.; Diemberger, I.
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
2024 Cecco, S.; Puligheddu, S.; Fusaroli, M.; Gerratana, L.; Yan, M.; Zamagni, C.; De Ponti, F.; Raschi, E.
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
2024 Fusaroli M.; Giunchi V.; Battini V.; Puligheddu S.; Khouri C.; Carnovale C.; Raschi E.; Poluzzi E.
Environmental sustainability-an essential component of rational use of medicines
2024 Giunchi, V; Fusaroli, M; Linder, E; Villén, J; Raschi, E; Lunghi, C; Wettermark, B; Poluzzi, E; Nekoro, M
Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports A Note of Caution
2024 Fusaroli, M.; Khouri, C.; Poluzzi, E.; De Ponti, F.; Salvo, F.; Raschi, E.
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase
2024 Noseda, R.; Bedussi, F.; Giunchi, V.; Fusaroli, M.; Raschi, E.; Ceschi, A.
The evolving role of disproportionality analysis in pharmacovigilance
2024 Fusaroli, M.; Raschi, E.; Poluzzi, E.; Hauben, M.
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
2024 Fusaroli, M.; Salvo, F.; Begaud, B.; Alshammari, T. M.; Bate, A.; Battini, V.; Brueckner, A.; Candore, G.; Carnovale, C.; Crisafulli, S.; Cutroneo, P. M.; Dolladille, C.; Drici, M. -D.; Faillie, J. -L.; Goldman, A.; Hauben, M.; Herdeiro, M. T.; Mahaux, O.; Manlik, K.; Montastruc, F.; Noguchi, Y.; Noren, G. N.; Noseda, R.; Onakpoya, I. J.; Pariente, A.; Poluzzi, E.; Salem, M.; Sartori, D.; Trinh, N. T. H.; Tuccori, M.; van Hunsel, F.; van Puijenbroek, E.; Raschi, E.; Khouri, C.
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration
2024 Fusaroli, M.; Salvo, F.; Begaud, B.; Alshammari, T. M.; Bate, A.; Battini, V.; Brueckner, A.; Candore, G.; Carnovale, C.; Crisafulli, S.; Cutroneo, P. M.; Dolladille, C.; Drici, M. -D.; Faillie, J. -L.; Goldman, A.; Hauben, M.; Herdeiro, M. T.; Mahaux, O.; Manlik, K.; Montastruc, F.; Noguchi, Y.; Noren, G. N.; Noseda, R.; Onakpoya, I. J.; Pariente, A.; Poluzzi, E.; Salem, M.; Sartori, D.; Trinh, N. T. H.; Tuccori, M.; van Hunsel, F.; van Puijenbroek, E.; Raschi, E.; Khouri, C.
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline
2024 Fusaroli, M.; Salvo, F.; Khouri, C.; Raschi, E.
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
2024 Fusaroli, M.; Polizzi, S.; Menestrina, L.; Giunchi, V.; Pellegrini, L.; Raschi, E.; Weintraub, D.; Recanatini, M.; Castellani, G.; De Ponti, F.; Poluzzi, E.
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
2023 Pauline O.; Robert M.; Bernardeau C.; Hlavaty A.; Fusaroli M.; Roustit M.; Cracowski J.L.; Khouri C.
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct
2023 Fusaroli M.; Pellegrini L.; Fusaroli R.; Raschi E.; Menchetti M.; Poluzzi E.
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
2023 Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
2023 Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, Rita; Potena, Luciano
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach
2023 Giunchi, Valentina; Fusaroli, Michele; Hauben, Manfred; Raschi, Emanuel; Poluzzi, Elisabetta
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
2023 Fusaroli M.; Pelletti G.; Giunchi V.; Pugliese C.; Bartolucci M.; Necibi E.N.; Raschi E.; De Ponti F.; Pelotti S.; Poluzzi E.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Characterizing post-mortem blood concentrations in methadone-related deaths | Pelletti, Guido; Giunchi, Valentina; Fais, Paolo; Innocenti, Mattia; Giorgetti, Arianna; Poluzzi,... Elisabetta; Fusaroli, Michele; Pelotti, Susi | 2026-01-01 | INTERNATIONAL JOURNAL OF LEGAL MEDICINE | - | 1.01 Articolo in rivista | unpaywall-bitstream-1907382410.pdf; 414_2025_3620_MOESM1_ESM.docx |
| Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study | Bernardeau, Claire; Revol, Bruno; Salvo, Francesco; Fusaroli, Michele; Raschi, Emanuel; Cracowski..., Jean-Luc; Roustit, Matthieu; Khouri, Charles | 2025-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | Bernardeux_DrugSafety_2025.pdf; 40264_2025_1524_MOESM1_ESM.pdf |
| Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency | Giunchi, Valentina; Fusaroli, Michele; Cangini, Agnese; Fortinguerra, Filomena; Zito, Simona; Pie...rantozzi, Andrea; Lunghi, Carlotta; Poluzzi, Elisabetta; Trotta, Francesco | 2025-01-01 | BJCP. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | Brit J Clinical Pharma - 2025 - Giunchi - Assessing the environmental impact of medicines in Italy using data from the.pdf |
| Ivabradine, atrial fibrillation and stroke: a combined meta-analysis and FAERS disproportionality analysis | Spadotto, A.; Fusaroli, M.; Carelli, M.; Nardi, E.; Amadori, M.; Massaro, G.; De Angelis, V.; Gat...ti, M.; Ciubine, V.; Raschi, E.; Poluzzi, E.; Diemberger, I. | 2025-01-01 | FRONTIERS IN PHARMACOLOGY | - | 1.01 Articolo in rivista | fphar-16-1638923.pdf; Supplementary file 1.docx |
| Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System | Cecco, S.; Puligheddu, S.; Fusaroli, M.; Gerratana, L.; Yan, M.; Zamagni, C.; De Ponti, F.; Rasch...i, E. | 2024-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS | Fusaroli M.; Giunchi V.; Battini V.; Puligheddu S.; Khouri C.; Carnovale C.; Raschi E.; Poluzzi E. | 2024-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | s40264-023-01391-4.pdf; 40264_2023_1391_MOESM1_ESM.docx |
| Environmental sustainability-an essential component of rational use of medicines | Giunchi, V; Fusaroli, M; Linder, E; Villén, J; Raschi, E; Lunghi, C; Wettermark, B; Poluzzi, E; N...ekoro, M | 2024-01-01 | INTERNATIONAL JOURNAL OF PHARMACY PRACTICE | - | 1.01 Articolo in rivista | - |
| Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports A Note of Caution | Fusaroli, M.; Khouri, C.; Poluzzi, E.; De Ponti, F.; Salvo, F.; Raschi, E. | 2024-01-01 | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | - | 1.01 Articolo in rivista | - |
| Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase | Noseda, R.; Bedussi, F.; Giunchi, V.; Fusaroli, M.; Raschi, E.; Ceschi, A. | 2024-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | e009902.full.pdf |
| The evolving role of disproportionality analysis in pharmacovigilance | Fusaroli, M.; Raschi, E.; Poluzzi, E.; Hauben, M. | 2024-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement | Fusaroli, M.; Salvo, F.; Begaud, B.; Alshammari, T. M.; Bate, A.; Battini, V.; Brueckner, A.; Can...dore, G.; Carnovale, C.; Crisafulli, S.; Cutroneo, P. M.; Dolladille, C.; Drici, M. -D.; Faillie, J. -L.; Goldman, A.; Hauben, M.; Herdeiro, M. T.; Mahaux, O.; Manlik, K.; Montastruc, F.; Noguchi, Y.; Noren, G. N.; Noseda, R.; Onakpoya, I. J.; Pariente, A.; Poluzzi, E.; Salem, M.; Sartori, D.; Trinh, N. T. H.; Tuccori, M.; van Hunsel, F.; van Puijenbroek, E.; Raschi, E.; Khouri, C. | 2024-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | s40264-024-01421-9.pdf; 40264_2024_1421_MOESM1_ESM.pdf |
| The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration | Fusaroli, M.; Salvo, F.; Begaud, B.; Alshammari, T. M.; Bate, A.; Battini, V.; Brueckner, A.; Can...dore, G.; Carnovale, C.; Crisafulli, S.; Cutroneo, P. M.; Dolladille, C.; Drici, M. -D.; Faillie, J. -L.; Goldman, A.; Hauben, M.; Herdeiro, M. T.; Mahaux, O.; Manlik, K.; Montastruc, F.; Noguchi, Y.; Noren, G. N.; Noseda, R.; Onakpoya, I. J.; Pariente, A.; Poluzzi, E.; Salem, M.; Sartori, D.; Trinh, N. T. H.; Tuccori, M.; van Hunsel, F.; van Puijenbroek, E.; Raschi, E.; Khouri, C. | 2024-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | s40264-024-01423-7 (1).pdf |
| The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline | Fusaroli, M.; Salvo, F.; Khouri, C.; Raschi, E. | 2024-01-01 | FRONTIERS IN PHARMACOLOGY | - | 1.01 Articolo in rivista | fphar-15-1488725.pdf; Data Sheet 1.PDF |
| Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System | Fusaroli, M.; Polizzi, S.; Menestrina, L.; Giunchi, V.; Pellegrini, L.; Raschi, E.; Weintraub, D....; Recanatini, M.; Castellani, G.; De Ponti, F.; Poluzzi, E. | 2024-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | s40264-024-01471-z.pdf; 40264_2024_1471_MOESM1_ESM.pdf |
| Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database | Pauline O.; Robert M.; Bernardeau C.; Hlavaty A.; Fusaroli M.; Roustit M.; Cracowski J.L.; Khouri C. | 2023-01-01 | BIODRUGS | - | 1.01 Articolo in rivista | - |
| Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct | Fusaroli M.; Pellegrini L.; Fusaroli R.; Raschi E.; Menchetti M.; Poluzzi E. | 2023-01-01 | ADDICTION | - | 1.01 Articolo in rivista | Behavioral excess and disruptive conduct A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic construct.pdf |
| Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors | Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, ...Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco | 2023-01-01 | JTO CLINICAL AND RESEARCH REPORTS | - | 1.01 Articolo in rivista | Sisi et al. JTO CCR 23.pdf; Sisi et al. JTO CCR supplementary 23.pdf |
| Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians | Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, ...Rita; Potena, Luciano | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | Raschi et al., Drug Safety Cardiotoxicity ICI 2023.pdf; 40264_2023_1320_MOESM1_ESM.pdf |
| Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach | Giunchi, Valentina; Fusaroli, Michele; Hauben, Manfred; Raschi, Emanuel; Poluzzi, Elisabetta | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System | Fusaroli M.; Pelletti G.; Giunchi V.; Pugliese C.; Bartolucci M.; Necibi E.N.; Raschi E.; De Pont...i F.; Pelotti S.; Poluzzi E. | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | s40264-022-01269-x.pdf; 40264_2022_1269_MOESM1_ESM.pdf |